Birchbrook’s CRISPR Therapeutics CRSP Stock Holding History

Birchbrook’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.1K	Hold	405	–	–	0.01%	166
2026 Q1	$19.3K	Hold	405	–	–	0.01%	164
2025 Q4	$21.2K	Sell	405 -645	-61%	-$38.6K	0.01%	169
2025 Q3	$68.1K	Hold	1,050	–	–	0.04%	115
2025 Q2	$51.1K	Buy	1,050 +1,000	+2,000%	+$38.7K	0.03%	124
2025 Q1	$1.7K	Hold	50	–	–	﹤0.01%	238
2024 Q4	$1.97K	Hold	50	–	–	﹤0.01%	257
2024 Q3	$2.35K	Hold	50	–	–	﹤0.01%	236
2024 Q2	$2.7K	Hold	50	–	–	﹤0.01%	235
2024 Q1	$3.41K	Hold	50	–	–	﹤0.01%	237
2023 Q4	$3.13K	Buy	+50	New	+$2.76K	﹤0.01%	259

Other funds holding CRSP

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Birchbrook's CRSP Position: Q2 2026 in Review

Birchbrook held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 405 shares worth $22.1K. The position accounts for 0.01% of the portfolio, ranked #166.

Birchbrook first reported a position in CRSP in Q4 2023 and has held it in 11 quarters since. The position peaked at $68.1K in Q3 2025. 167 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Birchbrook held 405 shares of CRISPR Therapeutics worth $22.1K as of Q2 2026.
Birchbrook left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up 0.01% of Birchbrook's portfolio in Q2 2026, its #166 holding.
Birchbrook first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 11 quarters since.
Birchbrook's CRISPR Therapeutics position peaked at $68.1K in Q3 2025.
167 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Birchbrook's 13F filing for Q2 2026, filed 9 Jul 2026.